



Figure S1 The absolute standardized mean differences for the balance of covariates between the two groups. MI, myocardial infarction; CCI, Charlson comorbidity index; HR, hazard ratio; CHF, congestive heart failure; DBP, diastolic blood pressure; APSIII, Acute Physiology Score III; RR, respiratory rate; AKI, acute kidney injury; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure; SMD, standard mean deviation; IPTW, inverse-probability-of-treatment weighted; SMRW, standardized mortality ratio weighted; PA, pairwise algorithmic; OW, overlap weighting.

Table S1 Multivariable analysis of the entire cohort (n=50,624)

Variables	Total, n	28-day mortality, n (%)	HR (95% CI)	P value
Model 1: statin use				
No statins	34,994	5,232 (15.0)	1 (reference)	
Statins	15,630	1,236 (7.9)	0.66 (0.61–0.70)	<0.001
Model 2: type of statin				
No statins	34,994	5,232 (15.0)	1 (reference)	
Atorvastatin	9,593	822 (8.6)	0.71 (0.66–0.78)	<0.001
Rosuvastatin	1,152	68 (5.9)	0.57 (0.45–0.72)	<0.001
Simvastatin	3,710	248 (6.7)	0.54 (0.48–0.62)	<0.001
Other statins	1,175	98 (8.3)	0.68 (0.56–0.83)	<0.001

HR, hazard ratio; CI, confidence interval.